Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Biol. Res ; 53: 56-56, 2020. ilus, graf
Article in English | LILACS | ID: biblio-1505782

ABSTRACT

BACKGROUND: Neuronal apoptosis plays a critical event in the pathogenesis of early brain injury after subarachnoid hemorrhage (SAH). This study investigated the roles of Tauroursodeoxycholic acid (TUDCA) in attenuate neuronal apoptosis and underlying mechanisms after SAH. METHODS: Sprague-Dawley rats were subjected to model of SAH and TUDCA was administered via the internal carotid injection. Small interfering RNA (siRNA) for TGR5 were administered through intracerebroventricular injection 48 h before SAH. Neurological scores, brain water content, Western blot, TUNEL staining and immunofluorescence staining were evaluated. RESULTS: TUDCA alleviated brain water content and improved neurological scores at 24 h and 72 h after SAH. TUDCA administration prevented the reduction of SIRT3 and BCL-2 expressions, as well as the increase of BAX and cleaved caspase-3.Endogenous TGR5 expression were upregulated after SAH and treatment with TGR5 siRNA exacerbated neurological outcomes after SAH and the protective effects of TUDCA at 24 h after SAH were also abolished by TGR5 siRNA. CONCLUSIONS: Our findings demonstrate that TUDCA could attenuated neuronal apoptosis and improve neurological functions through TGR5/ SIRT3 signaling pathway after SAH. TUDCA may be an attractive candidate for anti-apoptosis treatment in SAH.


Subject(s)
Animals , Male , Rats , Subarachnoid Hemorrhage/drug therapy , Taurochenodeoxycholic Acid/therapeutic use , Apoptosis , Sirtuins/physiology , Receptors, G-Protein-Coupled/physiology , Neurons/pathology , Rats, Sprague-Dawley , Neurons/drug effects
2.
Yonsei Medical Journal ; : 413-419, 2011.
Article in English | WPRIM | ID: wpr-95679

ABSTRACT

PURPOSE: Stimulation of human aortic smooth muscle cells (hAoSMCs) with native low-density lipoprotein (nLDL) induced the production of interleukin-8 (IL-8) that is involved in the pathogenesis of cardiovascular diseases. However, the process of signal transduction of nLDL was currently uncharacterized. Therefore, the aim of this study was to investigate the signal transduction pathway of nLDL-dependent IL-8 production and the effect of IL-8 on hAoSMCs migration. MATERIALS AND METHODS: nLDL was prepared by ultracentrifugation with density-adjusted human serum of normocholesterolemia. In hAoSMCs, IL-8 secreted to medium was measured using ELISA assay, and Western blot analysis was performed to detect p38 MAPK activation as a key regulator of IL-8 production. nLDL-dependent H2O2 generation was determined by microscopic analysis using 2',7'-dichlorofluoroscein diacetate (DCF-DA). IL-8-induced migration of hAoSMCs was evaluated by counting the cell numbers moved to lower chamber using Transwell plates. RESULTS: nLDL-induced IL-8 production was completely blocked by preincubation of hAoSMCs with pertussis toxin (PTX), which inhibited nLDL-dependent p38 MAPK phosphorylation. PTX-sensitive G-protein coupled receptor was responsible for nLDL-dependent H2O2 generation that was abrogated with preincubation of the cells with of polyethylene glycol-conjugated catalase (PEG-Cat). Pretreatment of PEG-Cat prevented nLDL-induced p38 MAPK phosphorylation and IL-8 production, which was partly mimicked by treatment with exogenous H2O2. Finally, IL-8 increased hAoSMCs migration that was completely blocked by incubation with IL-8 neutralizing antibody. CONCLUSION: PTX-sensitive G-protein coupled receptor-dependent H2O2 generation by nLDL plays a critical role in IL-8 production in hAoSMC, and IL-8 may contribute to atherogenesis through increased migration of hAoSMCs.


Subject(s)
Humans , Cell Movement/physiology , Cells, Cultured , Hydrogen Peroxide/metabolism , Interleukin-8/biosynthesis , Lipoproteins, LDL/pharmacology , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/cytology , Pertussis Toxin/pharmacology , Phosphorylation/drug effects , Reactive Oxygen Species/metabolism , Receptors, G-Protein-Coupled/physiology , Signal Transduction , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Rev. argent. endocrinol. metab ; 47(4): 24-28, oct.-dic. 2010.
Article in English | LILACS | ID: lil-641980

ABSTRACT

El GPRC6A es un miembro recientemente identificado de la familia C de receptores acoplados a proteínas G (GPCRs) que está estrechamente emparentado con el receptor sensor de calcio (CASR). Se ha demostrado que este receptor es capaz de sensar cationes extracelulares y aminoácidos y que requiere tanto de los cationes extracelulares y de los aminoácidos para su óptima estimulación in vitro. El estudio del perfil de ligandos ha mostrado que la l-ornithine es el más potente eficaz l-aminoácido agonista seguido de varios otros aminoácidos alifáticos, neutros, y básicos. Algunos estudios han mostrado la activación por cationes del GPRC6A, pero comparado con el CASR, se necesitan concentraciones extracelulares más altas de calcio para activar este receptor. Es más, el Mg(2+) ha mostrado ser un modulador positivo de la respuesta a la l-ornithine. Se lo ha propuesto como el candidato para el elusivo mecanismo de sensado de calcio extracelular del osteoblasto, que se sabe responde a altas concentraciones locales de Ca²+. También se ha propuesto al GPRC6A como candidato a receptor de la osteocalcina, regulando el metabolismo energético y como blanco molecular para la acción del estroncio sobre el hueso.


GPRC6A is a recently identified member of family C of G protein-coupled receptors (GPCRs) that is closely related to the calcium-sensing receptor CASR. It has recently been shown that GPRC6A extracellular cations and amino acids and requires both extracellular cations and amino acids for optimal stimulation in vitro. The study of the ligand profile of GPRC6A has shown that l-ornithine is the most potent and efficacious l-amino acid agonist, followed by several other aliphatic, neutral, and basic amino acids. Some studies show cation-dependent activation of GPRC6A, but compared to CASR, much higher extracellular calcium concentrations are needed to activate this receptor. Furthermore, the divalent cation Mg(2+) was found to be a positive modulator of the l-ornithine response. GPRC6A may be a candidate for the elusive extracellular calcium-sensing mechanism known to be present in osteoblasts, which respond to high local Ca²+ concentrations. GPRC6A has also been proposed as a candidate receptor for ostocalcin, regulating energy metabolism and as a molecular target for the action of strontium on bone.


Subject(s)
Receptors, G-Protein-Coupled/analysis , Receptors, G-Protein-Coupled/physiology , Osteoblasts , Strontium/therapeutic use , Osteocalcin/agonists
4.
An. acad. bras. ciênc ; 81(3): 321-344, Sept. 2009.
Article in English | LILACS | ID: lil-523966

ABSTRACT

This review focuses on the expression and function of muscarinic acetylcholine receptors (mAChRs), α1-adrenoceptors and relaxin receptors in the male reproductive tract. The localization and differential expression of mAChR and α1-adrenoceptor subtypes in specific compartments of the efferent ductules, epididymis, vas deferens, seminal vesicle and prostate of various species indicate a role for these receptors in the modulation of luminal fluid composition and smooth muscle contraction, including effects on male fertility. Furthermore, the activation of mAChRs induces transactivation of the epidermal growth factor receptor (EGFR) and the Sertoli cell proliferation. The relaxin receptors are present in the testis, RXFP1 in elongated spermatids and Sertoli cells from rat, and RXFP2 in Leydig and germ cells from rat and human, suggesting a role for these receptors in the spermatogenic process. The localization of both receptors in the apical portion of epithelial cells and smooth muscle layers of the vas deferens suggests an involvement of these receptors in the contraction and regulation of secretion.


Esta revisão enfatiza a expressão e a função dos receptores muscarínicos, adrenoceptores α1 e receptores para relaxina no sistema reprodutor masculino. A expressão dos receptores muscarínicos e adrenoceptores α1 em compartimentos específicos de dúctulos eferentes, epidídimo, ductos deferentes, vesícula seminal e próstata de várias espécies indica o envolvimento destes receptores na modulação da composição do fluido luminal e na contração do músculo liso, incluindo efeitos na fertilidade masculina. Além disso, a ativação dos receptores muscarínicos leva à transativação do receptor para o fator crescimento epidermal e proliferação das células de Sertoli. Os receptores para relaxina estão presentes no testículo, RXFP1 nas espermátides alongadas e células de Sertoli de rato e RXFP2 nas células de Leydig e germinativas de ratos e humano, sugerindo o envolvimento destes receptores no processo espermatogênico. A localização de ambos os receptores na porção apical das células epiteliais e no músculo liso dos ductos deferentes de rato sugere um papel na contração e na regulação da secreção.


Subject(s)
Animals , Guinea Pigs , Humans , Male , Rats , Genitalia, Male/physiology , Receptors, Adrenergic, alpha-1/physiology , Receptors, G-Protein-Coupled/physiology , Receptors, Muscarinic/physiology , Receptors, Peptide/physiology , Genitalia, Male/chemistry , Receptors, Adrenergic, alpha-1/metabolism , Receptors, G-Protein-Coupled/metabolism , Receptors, Muscarinic/metabolism , Receptors, Peptide/metabolism
5.
ARBS annu. rev. biomed. sci ; 11(n.esp): T51-T85, 20090000. ilus
Article in English | LILACS | ID: lil-560451

ABSTRACT

Family A G-protein coupled receptors (AGPCRs) form the largest group of correlate receptors whose structure, a bundle of seven-trans-membrane (7 TM) helices, may be activated thus becoming able to transduce a signal from the extracellular medium to the cytosol. This activation may be constitutional, for instance due to permanent structural modifications, or be physiologically triggered by agonist binding at an external and accessible specific site. Based on thestructures of agonists, AGPCRs may be divided according to pharmacological assays into many classes of receptors, each one comprising many types or sub-types of proteins, as differentiated by specific binding of inhibitors, all of them performing a multitude of functions. It is noteworthy that AGPCRs have been more recently cloned and their sequences of amino acids determined in a large scale, a condition that has allowed these receptors to be sorted by a new criterium. Sequence analyses have consistently matched functional assays for classification of AGPCRs except for a certain number of functionally unknown receptors which have been cataloged as orphan receptors. A colossal number of AGPCRs, more than 10,000 sequences belonging to more than 1,000 different types of receptors, may nowadays be multiply-aligned what has been enabling the determination of parameters of residue conservation and characterization of special motifs along the structure of these proteins. There are at the present time, high-resolution 3D structures for the following AGPCRs: inactive rhodopsin, retinal-free opsin, Beta adrenoceptor and adenosine receptors. Among them, hodopsin structures are reliable enough to be used as prototypes for analyses of residue conservation and mechanisms of activation of receptors, specially at the level of the more conserved structure in the cytosolic half of their 7TM bundle.


Subject(s)
Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/classification , Receptors, G-Protein-Coupled/physiology , Adenosine , Receptors, Adrenergic , Rhodopsin
6.
Arq. bras. cardiol ; 90(5): 374-380, maio 2008. ilus
Article in English, Portuguese | LILACS | ID: lil-482931

ABSTRACT

A apelina é um peptídeo recentemente descoberto e identificado como o ligando endógeno do receptor APJ. A apelina e o receptor APJ são expressos numa grande variedade de tecidos, tais como coração, cérebro, rins e pulmões, onde a sua interação pode ter importantes efeitos fisiopatológicos. Com efeito, a última década foi fértil no esclarecimento de possíveis papéis desempenhados pela apelina na fisiologia humana, nomeadamente como peptídeo regulador dos sistemas cardiovascular, hipotálamo-hipófisário, gastrointestinal e imunitário. Um possível envolvimento da apelina na patogênese de doenças com elevada prevalência e co-morbilidades, como a hipertensão arterial, a insuficiência cardíaca e o diabete melito tipo 2, perspectivam-na como um possível alvo terapêutico a explorar no futuro. Este trabalho fornece uma visão geral dos efeitos fisiológicos da apelina e apresenta o possível papel desse peptídeo na patogênese de várias doenças, associado a implicações terapêuticas que poderão vir a ser, assim, exploradas.


Apelin is a recently discovered peptide, identified as an endogenous ligand of receptor APJ. Apelin and receptor APJ are expressed in a wide variety of tissues including heart, brain, kidneys and lungs. Their interaction may have relevant pathophysiologic effects in those tissues. In fact, the last decade has been rich in illustrating the possible roles played by apelin in human physiology, namely as a regulating peptide of cardiovascular, hypothalamus-hypophysis, gastrointestinal, and immune systems. The possible involvement of apelin in the pathogenesis of high prevalence conditions and comorbidities - such as hypertension, heart failure, and Diabetes Mellitus Type 2 (T2DM) - rank it as a likely therapeutic target to be investigated in the future. The present paper is an overview of apelin physiologic effects and presents the possible role played by this peptide in the pathogenesis of a number of conditions as well as the therapeutic implications that might, therefore, be investigated.


Subject(s)
Humans , Cardiovascular Physiological Phenomena , Cardiovascular Diseases/physiopathology , Intercellular Signaling Peptides and Proteins/physiology , Receptors, G-Protein-Coupled/physiology , /physiopathology , Heart Failure/physiopathology , Hypertension/physiopathology
7.
Article in English | IMSEAR | ID: sea-18419

ABSTRACT

G-protein coupled receptors (GPCR) tend to desensitize/internalize when exposed to excess agonist.Previously, we have supported the argument that in the case of the oxytocin receptor (OTR), excess agonist (oxytocin, OT) at birth could be implicated with behavioural disorders of the autistic spectrum. In this review, more recent evidence for this hypothesis is summarized, and it is juxtaposed against reports where exogenous OT was found beneficial in alleviating certain undesired behaviours. Facing this dichotomy, we suggest possible in silico drug discovery approaches to mitigate undesired side effect of OT administration/OTR desensitization, especially in the light of potentially emerging agonist therapies. For this, the most important structural features of OTR are reviewed, and we highlight here the need for higher level of theory studies at the easier approachable extracellular receptor side, where loop 3(e3) and the N-terminated strain of OTR appear to offer targets of particular interest for the development of an agent that conditions the action of excess OT. Another approach, based on the development of new agonists with an improved receptor activation to receptor phosphorylation ratio, is also discussed. Finally, the issue of OTR desensitization is put into the broader context of GPCR desensitization and possible implications for behavioural disorders, and the case is made for the usefulness of computational studies in this area.


Subject(s)
Animals , Autistic Disorder/drug therapy , Humans , Oxytocin/pharmacology , Receptors, G-Protein-Coupled/physiology , Receptors, Oxytocin/chemistry
8.
Braz. j. med. biol. res ; 39(8): 1003-1011, Aug. 2006. graf
Article in English | LILACS | ID: lil-433165

ABSTRACT

Growth hormone secretion is classically modulated by two hypothalamic hormones, growth hormone-releasing hormone and somatostatin. A third pathway was proposed in the last decade, which involves the growth hormone secretagogues. Ghrelin is a novel acylated peptide which is produced mainly by the stomach. It is also synthesized in the hypothalamus and is present in several other tissues. This endogenous growth hormone secretagogue was discovered by reverse pharmacology when a group of synthetic growth hormone-releasing compounds was initially produced, leading to the isolation of an orphan receptor and, finally, to its endogenous ligand. Ghrelin binds to an active receptor to increase growth hormone release and food intake. It is still not known how hypothalamic and circulating ghrelin is involved in the control of growth hormone release. Endogenous ghrelin might act to amplify the basic pattern of growth hormone secretion, optimizing somatotroph responsiveness to growth hormone-releasing hormone. It may activate multiple interdependent intracellular pathways at the somatotroph, involving protein kinase C, protein kinase A and extracellular calcium systems. However, since ghrelin has a greater ability to release growth hormone in vivo, its main site of action is the hypothalamus. In the current review we summarize the available data on the: a) discovery of this peptide, b) mechanisms of action of growth hormone secretagogues and ghrelin and possible physiological role on growth hormone modulation, and c) regulation of growth hormone release in man after intravenous administration of these peptides.


Subject(s)
Humans , Growth Hormone-Releasing Hormone/physiology , Human Growth Hormone/physiology , Peptide Hormones , Receptors, G-Protein-Coupled/physiology , Ghrelin , Growth Hormone-Releasing Hormone , Growth Hormone-Releasing Hormone/therapeutic use , Human Growth Hormone , Human Growth Hormone/therapeutic use , Oligopeptides/physiology , Peptide Hormones/physiology , Peptide Hormones/therapeutic use , Receptors, Ghrelin
9.
Arq. bras. endocrinol. metab ; 50(1): 17-24, fev. 2006. ilus, graf
Article in English | LILACS | ID: lil-425455

ABSTRACT

A secreção de hormônio de crescimento (HC) é modulada pelo hormônio liberador de HC e pela somatostatina. Na ultima década foi descoberto um terceiro mecanismo de controle, envolvendo os secretagogos de HC. A ghrelina é um peptídeo acilado, descoberto recentemente, que é produzido no estômago, porém também é sintetizado no hipotálamo. Este peptídeo é capaz de liberar HC, além de aumentar a ingestão alimentar. A ghrelina endógena parece amplificar o padrão básico de secreção de HC, ampliando a resposta do somatotrófo ao hormônio liberador de HC. Este peptídeo estimula múltiplas vias intracelulares interdependentes no somatotrófo, envolvendo a proteína quinase C, proteína quinase A e sistemas moduladores de cálcio extracelular. Entretanto, como a liberação de HC induzida pela ghrelina in vivo é mais acentuada que in vitro, seu local de atuação predominante é no hipotálamo. Nesse artigo apresentamos uma revisão sobre a descoberta da ghrelina, os dados existentes sobre os mecanismos de ação e possível papel fisiológico dos secretagogos de HC e da ghrelina na secreção de HC e, finalmente, os efeitos da administração endovenosa destes peptídeos sobre a secreção de HC no homem.


Subject(s)
Humans , Male , Female , Growth Hormone-Releasing Hormone/physiology , Growth Hormone , Peptide Hormones/physiology , Receptors, G-Protein-Coupled/physiology , Growth Hormone-Releasing Hormone/pharmacology , Growth Hormone/drug effects , Peptide Hormones/pharmacology , Receptors, G-Protein-Coupled/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL